Pharsight

Moviprep generic

Moviprep is a colon cleansing drug owned by Salix Pharmaceuticals. It contains several active ingredients including Ascorbic Acid, Polyethylene Glycol 3350, Potassium Chloride, Sodium Ascorbate, Sodium Chloride, and Sodium Sulfate. This drug was first authorized for market use on 2nd August 2006.

When will Moviprep generic be available?

The patents of Moviprep are projected to expire on 1st September 2024. Following the expiration, the release of Moviprep generics may occur. Patent expiration dates have a close relationship with the availability of generic versions.

Moviprep uses

Moviprep is primarily used for bowel preparation before colonoscopy. Its active ingredients help in causing bowel movements and liquid bowel output, effectively emptying the colon for a clear view during colonoscopy.

Moviprep patent expiration

Moviprep holds a total of two patents, none of which have yet expired. The last known expiration date of the patent (US7658914 titled 'Colon cleansing compositions') is set for the 1st of September 2024. Hereafter, the generic versions of Moviprep may become feasible. Below are the details of the patent:

EPO Oppostions filed on Moviprep

Moviprep dosage

Want to ask something?